Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Up 4,453.8% in April

Eliem Therapeutics, Inc. (NASDAQ:ELYM) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Based on an average daily trading volume, of 665,800 shares, the days-to-cover ratio is presently 0.9 days. Approximately 3.3% of the shares of the company are sold short.

Eliem Therapeutics Trading Up 17.4 %

Eliem Therapeutics stock opened at $3.98 on Friday. Eliem Therapeutics has a 12 month low of $2.34 and a 12 month high of $5.19. The stock’s 50 day moving average is $3.06 and its 200-day moving average is $2.80. The company has a market capitalization of $110.33 million, a price-to-earnings ratio of -2.71 and a beta of 0.51.

Institutional Investors Weigh In On Eliem Therapeutics

A hedge fund recently bought a new stake in Eliem Therapeutics stock. Cerity Partners LLC bought a new position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned about 0.05% of Eliem Therapeutics at the end of the most recent reporting period. 69.76% of the stock is owned by hedge funds and other institutional investors.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.